Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00 2022-10-05 pm EDT
113.46 USD   +4.48%
10/05European ADRs Move Sharply Lower in Wednesday Trading
MT
10/03Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
10/03European ADRs Surge Higher in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Morgan Stanley Cuts Price Target on Ascendis Pharma A/S to $148 From $152, Keeps Overweight Rating

08/11/2022 | 09:32am EDT


© MT Newswires 2022
All news about ASCENDIS PHARMA A/S
10/05European ADRs Move Sharply Lower in Wednesday Trading
MT
10/03Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
10/03European ADRs Surge Higher in Monday Trading
MT
10/03Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT..
AQ
10/03Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT..
CI
09/30Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
09/29Ascendis Pharma Added to Wedbush Best Ideas List
MT
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweigh..
MT
09/14Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 34,8 M 34,3 M 34,3 M
Net income 2022 -500 M -493 M -493 M
Net cash 2022 620 M 611 M 611 M
P/E ratio 2022 -12,8x
Yield 2022 -
Capitalization 6 428 M 6 337 M 6 337 M
EV / Sales 2022 167x
EV / Sales 2023 44,9x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 115,08 €
Average target price 146,23 €
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Jan Møller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprogøe Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-15.66%6 337
REGENERON PHARMACEUTICALS, INC.18.08%79 063
VERTEX PHARMACEUTICALS37.53%77 102
BIONTECH SE-46.64%33 432
WUXI APPTEC CO., LTD.-39.54%29 067
GENMAB A/S0.76%23 187